针对PDK/PDH轴,通过基于结构的虚拟查与体外和体内实验来逆转代谢异常
Jianda Yue1, Jiawei Xu1, Yekui Yin1
1The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha 410081, China; Peptide and Small Molecule Drug R&D Plateform, Furong Laboratory, Hunan Normal University, Changsha 410081, Hunan, China; Institute of Interdisciplinary Studies, Hunan Normal University, Changsha 410081, China.
研究人员发现了一种小分子g25,通过准pyruvate dehydrogenase kinase (PDK) 来激活pyruvate dehydrogenase (PDH). 这种分子通过改善能量代谢和减少脂肪,显示出治疗肥胖和糖尿病等代谢障碍的潜力.
科学领域:
- 生物化学 生物化学
- 代谢障碍 代谢障碍 代谢障碍
- 药物发现 药物发现 药物发现
背景情况:
- 酸盐脱酶激酶 (PDK) 蛋白在代谢障碍中过度激活,抑制酸盐脱酶 (PDH) 并损害能量和脂肪酸代谢.
- 调节PDH活性是治疗肥胖,糖尿病和癌症等代谢疾病的关键策略.
研究的目的:
- 识别和描述一个小分子,以PDK为目标,并激活PDH,用于潜在的治疗应用.
- 在代谢障碍和癌症的临床前模型中研究已识别的化合物的疗效.
主要方法:
- 多层次的计算选,以识别针对PDK的小分子 (g25).
- 在体外和体内实验中评估g25对PDH活性,代谢标志物和疾病模型的影响.
- 分子动力学模拟和激酶测试以确定g25的特异性.
主要成果:
- g25成功激活了PDH活性,并降低了血乳酸和甘油三水平.
- 在饮食诱导的肥胖小鼠模型中,g25降低了肝脏脂肪沉积.
- g25增强了思普拉丁的瘤抑制作用,并对PDK2.2表现出特异性.
结论:
- 用g25这样的化合物准PDK/PDH轴是一种有前途的代谢障碍治疗策略.
- g25作为PDK/PDH轴相关疾病的潜在化合物,为途径调节提供了洞察力.
更多相关视频
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Discovery: Overview
